Teitur Trophics, an Aarhus, Denmark-based biotech firm devoted to creating remedies for sufferers affected by neurodegenerative illnesses, raised EUR 28M in Collection A funding.
The spherical was led by Sunstone Life Science Ventures and Sound Bioventures, with participation from new traders, Industrifonden, Innovestor’s Life Science Fund and P53 Make investments. Together with the Collection A financing, Charles Massive will proceed as Chairman of the Board at Teitur, whereas Søren Lemonius, Casper Breum, Fredrik Lehmann, Milla Koistinaho and Susanne Stuffers will be part of the Teitur Board of Administrators.
The corporate intends to make use of the funds to progress its lead drug candidate, TT-P34, from candidate choice into scientific improvement, together with a Section 1b scientific examine in neurodegenerative illnesses.
Based by Simon Molgaard, Anders Dalby, Mathias Ollendorff and Simon Glerup, Teitur Trophics is a biotech firm that targets neurodegenerative illnesses. It’s creating round peptides for treating neurodegenerative problems the place there are not any remedies at the moment accessible, together with Parkinson’s Illness, Frontotemporal Dementia and Huntington’s Illness. Its lead drug candidate, TT-P34 works by clearing the poisonous protein deposits implicated in neurodegenerative illnesses, restoring the operate of mitochondria in affected mind cells and selling pro-survival signaling.
FinSMEs
14/03/2023
